What Comes After Pluvicto? A New and Distinct Prostate Cancer Patient Subpopulation Is Taking Shape

Why It Matters

The absence of an evidence‑based sequencing strategy after Pluvicto creates therapeutic uncertainty and may compromise outcomes for a growing cohort of advanced prostate cancer patients. Clarifying post‑radioligand options will shape clinical practice, drug development, and reimbursement decisions.

Key Takeaways

• Lu‑177 PSMA therapy (Pluvicto) shows <50% response rate, limited durability
• No consensus guideline exists for treatment after Pluvicto failure
• Post‑Pluvicto patients remain PSMA‑positive, enabling next‑generation targeting
• Emerging “post‑Pluvicto” cohort is heterogeneous, growing as therapy moves earlier
• Clinical focus shifts from access to sequencing strategies beyond radioligand therapy

Pulse Analysis

The approval of lutetium‑177 vipivotide tetraxetan, marketed as Pluvicto, marked a watershed moment for metastatic castration‑resistant prostate cancer (mCRPC). By delivering targeted radiation to PSMA‑expressing cells, the radioligand achieved overall survival benefits that prompted rapid adoption across oncology centers in the United States and Europe. Investors responded with heightened valuations for radiopharmaceutical developers, and payer negotiations accelerated as real‑world data confirmed manageable safety. Yet enthusiasm has been tempered by the therapy’s modest response rate—often below 50 percent—and inevitable resistance, underscoring the need for a clear post‑treatment roadmap.

Clinicians now confront a growing “post‑Pluvicto” cohort that is biologically distinct yet poorly defined. Patients may have entered therapy with borderline PSMA uptake, progressed despite an initial response, or remain PSMA‑positive while developing resistance mechanisms such as DNA repair alterations or neuroendocrine transdifferentiation. Existing ASCO, ESMO and NCCN guidelines stop short of prescribing a next line, leaving physicians to extrapolate from chemotherapy, next‑generation ARPIs, or emerging immunotherapies. This therapeutic vacuum fuels off‑label use and compels academic groups to launch phase II trials exploring combination regimens, dose‑intensified radioligands, and novel PSMA‑directed bispecific antibodies.

From a commercial perspective, the uncertainty creates both risk and opportunity. Firms are racing to develop second‑generation PSMA agents that can overcome resistance, while startups leverage antibody‑drug conjugates and CAR‑T platforms to exploit persistent PSMA expression. Payers will likely demand comparative effectiveness data before endorsing sequential radioligand therapy, prompting manufacturers to design head‑to‑head studies against taxane chemotherapy or novel hormonal agents. Establishing evidence‑based sequencing will improve outcomes, inform reimbursement, and solidify radiopharmaceuticals as a durable pillar of prostate‑cancer care.